Home / Business and Economy / Piramal Pharma Block Deal Sparks ₹1,750 Cr Fundraising
Piramal Pharma Block Deal Sparks ₹1,750 Cr Fundraising
13 Aug
Summary
- A block deal is planned to sell 6% of Piramal Pharma's equity.
- The transaction aims to raise approximately ₹1,750 crore.
- Company posted a Q1 net loss but saw significant revenue and EBITDA growth.
Piramal Pharma is preparing for a significant block deal, with plans to sell approximately 6% of the company's total equity. This transaction is anticipated to generate around ₹1,750 crore, potentially at a slight discount to the current market price.
In its first quarter results, Piramal Pharma reported a consolidated net loss of ₹69.39 crore. However, this period also saw a substantial increase in revenue, which grew by 17.4% year-on-year to ₹2,269.9 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) experienced a remarkable surge of 82.9%, reaching ₹195.2 crore, with EBITDA margins expanding to 8.6%.
Chairperson Nandini Piramal expressed optimism, noting that all three business segments initiated fiscal year 2027 with robust mid-to-high teens revenue growth and notable EBITDA margin expansion. The CDMO business demonstrated broad-based growth, supported by strong order inflows and execution. The Complex Hospital Generics business maintained its market leadership, while the Consumer Healthcare business continued its strong trajectory, driven by Power Brands and e-commerce sales.
